Coverage for AposHealth’s revolutionary non-invasive treatment for knee osteoarthritis is now available to federal agencies including the U.S. Department of Veterans Affairs which serves more than 9 million Veterans nationwide
NEW YORK, April 28, 2022 – AposHealth®, a disruptive global company focused on revolutionizing the treatment of musculoskeletal conditions such as knee osteoarthritis, has been awarded a five-year VA Federal Supply Schedule (FSS) contract effective through February 28, 2027. The FSS contract award enables hundreds of federal, Tribal, and qualified nonprofit customers, including the Department of Veterans Affairs, to purchase Apos® for eligible patients with knee osteoarthritis.
The patient-centric, at-home, evidence-based, non-invasive Apos® program is clinically proven to reduce pain1 and restore healthy walking patterns2 using a customized foot-worn device to offload pressure from painful areas. The treatment is delivered through the placement of proprietary pods on the bottom of a discreet foot-worn Apos® device that redistributes the body’s weight and retrains muscular coordination. Patients wear their Apos® for short periods of time each day while going about their regular routines.
The Veterans Health Administration is the largest integrated health care system in the US, providing care to more than nine million Veterans at 1,293 healthcare facilities throughout the US, Puerto Rico, and other US territories. Under the contract, eligible Veterans and other federal healthcare consumers will have access to Apos®’ innovative system.
According to a 2013 National Health Interview Survey,3 Veterans are more likely to have suffered musculoskeletal conditions, such as knee pain and arthritis, than the general population – which shows an elevated need for a clinically proven, non-invasive, drug-free treatment. According to the Department of Veterans Affairs’ website,4 “Musculoskeletal (MSK) conditions are the number one reason Veterans seek treatment at VA [facilities].”
“To the American Veterans who have worked so hard to secure our freedom, we are proud to be able to support them with innovative technology that has given so many individuals the freedom to move, live, and thrive,” says Cliff Bleustein, MD, MBA, President and CEO of AposHealth. “This is a wonderful opportunity for the Veteran community and other beneficiaries of the Federal Supply Schedule to gain access to this breakthrough medical technology and for AposHealth as a company to further extend its commercial reach.”
There are over 60 peer-reviewed publications supporting the science behind Apos® as well as its clinical effect. A May 2020 study1 published in the Journal of the American Medical Association demonstrated that after six months of treatment, knee osteoarthritis patients treated with Apos® reported 70% pain reduction on average (compared to 35% in the active controls). Clinical studies have also shown improvement in function1 and quality of life,2 alongside a significant reduction in pain medication use5 and invasive surgery6 among patients with knee osteoarthritis.
The Contract award number #36F79722D0082 enables the VA and other federal organizations to purchase Apos® at pre-approved pricing via the Veterans Administration’s FSS Contract or via the GSA Advantage Online Catalog. Veterans who want to learn more and see if they qualify for Apos® should visit https://StartApos.com/Veterans or call 888-806-1977 to speak with a representative.
About AposHealth®
At AposHealth®, we are passionate about revolutionizing the treatment of musculoskeletal conditions simply, by addressing peoples’ gait to help them move better, live better, and alleviate pain. Our flagship solution, Apos®, is FDA-cleared to temporarily reduce knee pain caused by osteoarthritis. It can also be used as a general wellness device to help patients live well with chronic lower back and hip pain. With a 96 percent satisfaction rate,7 over 110,000 patients treated, and over 60 peer-reviewed clinical studies in leading medical journals, this system—consisting of gait analysis, personalized foot-worn device, and a customized treatment plan—has helped patients worldwide move, live, and thrive. For more information, visit https://www.aposhealth.com.
Sources
1) Reichenbach S, Felson DT, Hincapié CA, et al. Effect of Biomechanical Footwear on Knee Pain in People With Knee Osteoarthritis: The BIOTOK Randomized Clinical Trial. JAMA. 2020;323(18):1802–1812.
2) Miles, C., Greene, A. The effect of treatment with a non-invasive foot worn biomechanical device on subjective and objective measures in patients with knee osteoarthritis- a retrospective analysis on a UK population. BMC Musculoskelet Disord 21, 386 (2020).
3) Hinojosa R, Hinojosa MS. Activity-Limiting Musculoskeletal Conditions in US Veterans Compared to Non-Veterans: Results from the 2013 National Health Interview Survey. PLoS One. 2016;11(12):e0167143. Published 2016 Dec 22.
4) https://www.womenshealth.va.gov/topics/musculoskeletal-conditions-and-pain.asp
5) Bar-Ziv, Y., Beer, Y., Ran, Y. et al. A treatment applying a biomechanical device to the feet of patients with knee osteoarthritis results in reduced pain and improved function: a prospective controlled study. BMC Musculoskelet Disord 11, 179 (2010).
6) Bar-Ziv Y, Debbi EM, Ran Y, et al. Long-Term Effects of AposTherapy in Patients with Osteoarthritis of the Knee: A Two-Year Followup. Arthritis. 2013 ;2013:689236.
7) Based on data captured at 3rd follow up appointment and is based on the commercial activity with NHS patients, treated between 2019-2020
